26S Proteasome p58 Inhibitors

26S Proteasome p58 inhibitors primarily operate through the inhibition of the chymotrypsin-like activity in the p58 subunit of the 26S proteasome. For instance, Bortezomib and Ixazomib are reversible inhibitors that bind to the chymotrypsin-like site of the p58 subunit. On the other hand, Carfilzomib and Oprozomib are irreversible inhibitors that selectively target the same site. These inhibitors can effectively halt the proteolytic function of the 26S proteasome, as the chymotrypsin-like site is crucial for its degradation activity. The inhibition is highly specific, with the compound forming either a reversible or irreversible complex with the p58 subunit.

Another set of compounds, like Lactacystin and Epoxomicin, act by forming a covalent adduct with the chymotrypsin-like site of the p58 subunit, thereby causing irreversible inhibition. PR-171, an analogue of Carfilzomib, follows a similar mechanism but is specifically designed to irreversibly inhibit p58. In contrast, PR-957 and PR-924 target the immunoproteasome, a variant of the 26S proteasome, and thereby indirectly affect p58. Other compounds like MG-132 offer broader inhibition, targeting not just the chymotrypsin-like activity but also other proteolytic functions within the proteasome. MLN2238, a prodrug of Ixazomib, offers a reversible form of inhibition, providing yet another method for the inhibition of p58. These inhibitors either directly or indirectly influence the p58 subunit, emphasizing the critical role it plays in the functional operation of the 26S proteasome.